USA TODAY International Edition

PFIZER TO BUY MIGRAINE TREATMENT DEVELOPER

-

cash influx to use by spending

$ 11.6 billion to venture deeper into a new treatment area. The vaccine and cancer drug maker said Tuesday it will use cash to buy the remaining portion of migraine treatment developer Biohaven Pharmaceut­ical it does not already own. Pfizer will pay $ 148.50 for each Biohaven share.

Newspapers in English

Newspapers from United States